The value of radiotherapy in treating recurrent prostate cancer after radical prostatectomy
- 1 December 2004
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Endocrinology
- Vol. 1 (2), 90-96
- https://doi.org/10.1038/ncpuro0056
Abstract
This review discusses the treatment options available to prostate cancer patients with disease recurrence following prostatectomy. It focuses on the use of radiotherapy, administered adjuvantly and as a salvage treatment. A nomogram that facilitates patient selection for salvage radiotherapy is presented. Approximately 25–40% of men who undergo radical retropubic prostatectomy (RRP) for the treatment of clinically localized prostate cancer will experience biochemical recurrence. A rapid prostate-specific antigen (PSA) doubling time or high-grade disease are risk factors for progression to bone metastases and cancer-specific mortality. Salvage external-beam radiotherapy (EBRT) to the prostate fossa is the only curative therapy for patients with biochemical recurrence after RRP, but it is used relatively infrequently to treat recurrent prostate cancer because of a widespread perception that most patients have systemic recurrence, and its reported lack of efficacy for high-risk disease. However, in a large, multicenter study of patients who received salvage EBRT for a rising PSA level after RRP, a substantial proportion of patients with high-grade disease and/or a rapid PSA doubling time were observed to have a favorable outcome after salvage EBRT if it was administered at low PSA values. This suggests that salvage EBRT could provide long-term cancer control for patients at the highest risk of progression to bone metastases and cancer-specific mortality. A nomogram that predicts the 3-year progression-free probability after salvage EBRT has been developed to facilitate the selection of patients for this potentially curative therapy. In the absence of other curative therapies, all patients with recurrent prostate cancer should be considered for salvage EBRT, particularly those with positive surgical margins. To be successful, salvage EBRT should be administered at the earliest evidence of recurrent disease, once a rising PSA trend as been confirmed.Keywords
This publication has 41 references indexed in Scilit:
- CANCER PROGRESSION AND SURVIVAL RATES FOLLOWING ANATOMICAL RADICAL RETROPUBIC PROSTATECTOMY IN 3,478 CONSECUTIVE PATIENTS: LONG-TERM RESULTSJournal of Urology, 2004
- Natural history of bone complications in men with prostate carcinoma initiating androgen deprivation therapyCancer, 2004
- Salvage radiation for a rising PSA following radical prostatectomyUrologic Oncology: Seminars and Original Investigations, 2004
- Patterns of Secondary Cancer Treatment for Biochemical Failure Following Radical Prostatectomy:: Data From CaPSUREJournal of Urology, 2004
- Indium-111–Capromab Pendetide Radioimmunoscintigraphy and Prognosis for Durable Biochemical Response to Salvage Radiation Therapy in Men After Failed ProstatectomyJournal of Clinical Oncology, 2003
- CANCER CONTROL WITH RADICAL PROSTATECTOMY ALONE IN 1,000 CONSECUTIVE PATIENTSJournal of Urology, 2002
- IS ANASTOMOTIC BIOPSY NECESSARY BEFORE RADIOTHERAPY AFTER RADICAL PROSTATECTOMY?Journal of Urology, 2001
- DEFINING PROSTATE SPECIFIC ANTIGEN PROGRESSION AFTER RADICAL PROSTATECTOMY: WHAT IS THE MOST APPROPRIATE CUT POINT?Journal of Urology, 2001
- PROSTATE SPECIFIC ANTIGEN ONLY PROGRESSION OF PROSTATE CANCERJournal of Urology, 2000
- LIMITED ROLE OF RADIONUCLIDE BONE SCINTIGRAPHY IN PATIENTS WITH PROSTATE SPECIFIC ANTIGEN ELEVATIONS AFTER RADICAL PROSTATECTOMYJournal of Urology, 1998